SCHEMBL721946

SCHEMBL721946

COC(=O)c1ccc(NC(c2oc3ncccc3c2C)C2CCCCC2)cc1

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RCE1 Q9Y256 1/20 0.44
ALDH1A1 P00352 4/20 0.41
NPC1 O15118 3/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
EPHX2 P34913 1/20 0.41
CYP2C19 P33261 2/20 0.40
MEN1 O00255 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
KMT2A Q03164 1/20 0.40
TEAD4 Q15561 1/20 0.37
EGLN1 Q9GZT9 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
KDM4E B2RXH2 2/20 0.36
RAB9A P51151 2/20 0.35
HPGD P15428 1/20 0.35
EPHX1 P07099 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL719620 0.91 RCE1 (0.54) RCE1ALDH1A1NPC1CYP2C19CYP1A2
SCHEMBL717537 0.86 RCE1 (0.48) RCE1ALDH1A1NPC1SMN1; SMN2EPHX2
SCHEMBL14905674 0.80 RCE1 (0.44) RCE1ALDH1A1NPC1SMN1; SMN2EPHX2
SCHEMBL719225 0.77 RCE1 (0.48) RCE1ALDH1A1NPC1SMN1; SMN2EPHX2
SCHEMBL14905708 0.77 NPC1 (0.48) ALDH1A1NPC1SMN1; SMN2EPHX2CYP2C19
SCHEMBL720334 0.76 RCE1 (0.59) RCE1ALDH1A1NPC1CYP2C19CYP1A2
SCHEMBL716365 0.76 NPC1 (0.40) RCE1ALDH1A1NPC1SMN1; SMN2EPHX2
SCHEMBL721148 0.76 NPC1 (0.40) RCE1ALDH1A1NPC1SMN1; SMN2EPHX2
SCHEMBL720765 0.75 MEN1 (0.41) ALDH1A1NPC1SMN1; SMN2EPHX2CYP2C19
SCHEMBL28290816 0.73 ALDH1A1 (0.52) RCE1ALDH1A1NPC1SMN1; SMN2EPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120270865-A2 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-25 US disclosed
US-20120053173-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-01 US disclosed
EP-2251326-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-11-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053173-A1 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP RCE1 2661/4885ALDH1A1 504/4885NPC1 902/4885
US-20120270865-A2 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP RCE1 2661/4885ALDH1A1 504/4885NPC1 902/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.